Micro-x Ltd. · ASX:MX1
Micro-x — Shareholder Meeting (November 2024)
14 slides from Micro-x's shareholder meeting presentation, Nov 12, 2024
Slide 1: 2024 Annual General Meeting – CEO Presentation
2024 ANNUAL GENERAL MEETING CEO Presentation K in gs ley Hal l Ch ief E xec uti ve Of fi cer 1 2 No vember 2 02 4 Micro-X Annual General Meeting 2024 I 1
Slide 2: Important Notice
IMPORTANT NOTICE S C O P E & L I M I T A T I O N S This Presentation has been prepared by Micro-X Limited (Micro-X or the Company) (ASX.MX1). The Presentation is a summary only and does not contain all the information about the Company’s assets and liabilities, financial position and performance, pr
Slide 3: Creating Revolutionary X-Ray Imaging to Better Lives
CREATING REVOLUTIONARY X -RAY IMAGING TO BETTER LIVES C u riou s I C oll ab or ativ e I D e term in ed Micro-X Annual General Meeting 2024 I 3 Micro-X FY24 Results | 3
Slide 4: Overview
OVERVI EW Building on commercial momentum from FY2024 1 Focus on execution – commercial revenue – funded development – strategic partners 2 Rover – record FY24 revenues – targeting larger opportunities and improved margins Argus – revised product strategy – combining backscatter + Pexray transmissio
Slide 5: Recent Achievements
R ECENT ACHIEVEMENTS New commercialisation strategies delivering milestones FY2024 FY2025 YTD Varex Tech Transfer Record Revenue - $15.2M Net operating cash $4.6M $7.5m collaboration agreement complete Driven by Mobile DR growth - ↑ 70% pcp Cash operating expenses1 ↓ 13% pcp Initial $100k generator
Slide 6: Our Priorities
OUR PR IOR ITIES Executing on identified priorities to drive commercialisation 1 Argus kit commercial traction in global defence and security markets 2 Build Micro-X Rover sales and distributor channels – self funded 3 Strategic partnerships for Checkpoints and Head CT products 4 Prototype Head CT u
Slide 7: Argus – Updated Products Strategy
A R G U S – U P D A T E D P R O D U C T S TR A T E G Y Combining backscatter with transmission for a compelling value proposition Customer demonstrations & feedback → Law enforcement, security and military → Challenge to break current operating practices using transmission images Redefined Argus kit
Slide 8: Rover – Targeting Larger Sales
R O VE R – T A R G E T I N G L A R GE R S A L E S Streamlined Mobile DR team delivering record revenues Sales up 70% in FY24 to $6.4M → Higher value orders and stronger price points – delivered improved margins Trial underway with a major US hospital & buying group → Second stage evaluation underway
Slide 9: Checkpoints Development – Momentum with DHS
CHEC KPOINT S DEV ELOPM ENT – M OM ENTUM W IT H DHS Achieving key deliverables under our two Department of Homeland Security contracts Baggage Scanner prototypes – supporting TSA testing → Initial prototype installed at DHS test laboratory in May 2024 → Second unit commissioned and completed to expa
Slide 10: Head CT Development – Progress to Trials
H EAD CT DEVELOP MENT –P ROGR ESS TO TRIA LS Strong imaging outcomes progressing towards diagnostic milestone Sagittal Transverse Coronal Single tube Proprietary technology developed → High voltage switching developed, refining mini tube imaging → First high voltage test bench array built with in-ho
Slide 11: New Strategic Partnerships
N E W S T R A T E G I C P A R T N E R SH I P S Realising value from our development work with the right strategic partners Varex – World’s largest OEM manufacturer → Two-year technology transfer completed - $7.5M received → Proof of concept – validates transferability of technology → Ongoing commerc
Slide 12: Outlook for FY25
O UT L OO K F OR FY 2 5 Key near-term operational objectives Commercial products Products In Development Corporate & Financial Argus Checkpoints Corporate > Commercial sales in security & defence > Deliver prototypes to demonstrate capability > Build and manage resources → Demonstrate new Argus kit
Slide 13: Corporate & Financials
COR POR ATE & F INA NCI AL S FINANCIALS & SHAREHOLDERS SHARE CAPITAL (11 November 2024) Cash ~A$3.0m (30 Sept 2024) Share price $0.068 per share $15.2m FY24 Revenue Revenue A$15.2m (FY2024) Total shares on issue 581.6 million Institutions + Perennial (12.2%), Varex Options (ex. 13.5c) 31.1 million $
Slide 14: Wrap Up
WRAP UP Five key take aways 1 Rover delivered record FY24 revenues – focused on large tender opportunities and conversion of inventory into cash – led by Chief Sales Officer Scott Bryant 2 Launch revised Argus kit combining backscatter and transmission imaging – continue to build interest and sales